Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Eli Lilly and Company
Nektar Therapeutics
Calithera Biosciences, Inc
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)